Since mammalian atria were recently found to contain vasoactive and natriuretic peptides, we investigated the following in normal humans: plasma human atrial natriuretic peptide concentrations, effective renal plasma flow (ERPF), glomerular filtration rate (GFR), urinary water and electrolyte excretion, blood pressure (BP), and catecholamine, antidiuretic hormone (ADH), angiotensin II, and aldosterone levels before, during, and after intravenous administration of the newly synthetized alpha-human atrial natriuretic peptide (ahANP).In 10 subjects ahANP given as an initial bolus of 50 Ag followed by a 45-min maintenance infusion at 6.25 jig/min (a) increased plasma ahANP from 58±12 to 625±87 (mean±SEM) pg/ml; (b) caused an acute fall in diastolic BP (-12%, P < 0.001) and a hemoconcentration (hematocrit +7%, P < 0.01) not fully explained by a negative body fluid balance; (c) increased GFR (+15%, P < 0.05) despite unchanged or decreased ERPF (filtration fraction +37%, P < 0.001); (d) augmented (P < 0.05-< 0.001) urinary chloride (+317%), sodium (+224%), calcium (+158%), magnesium (+110%), phosphate excretion (+88%), and free water clearance (from -0.76 to +2.23 ml/min, P < 0.001) with only little change in potassium excretion; and (e) increased plasma norepinephrine (P < 0.001) while plasma and urinary epinephrine and dopamine, and plasma ADH, angiotensin II, and aldosterone levels were unchanged. The magnitude and pattern of electrolyte and water excretion during ahANP infusion could not be accounted for by increased GFR alone.Therefore, in normal man, endogenous ahANP seems to circulate in blood. ahANP can cause a BP reduction and hemoconcentration which occur, at least in part, independently of diuresis and are accompanied by sympathetic activation. An increase in GFR that occurs in the presence of unchanged or even decreased total renal blood flow is an important but not sole mechanism of natriuresis and diuresis induced by ahANP in man.